191 related articles for article (PubMed ID: 33653918)
21. Mending Broken Hearts: A New Treatment Paradigm for Immune Checkpoint Inhibitor-Induced Myocarditis.
Bermas BL; Zaha VG
Circulation; 2021 Feb; 143(8):767-769. PubMed ID: 33617309
[No Abstract] [Full Text] [Related]
22. Association between myocarditis and other immune-related adverse events secondary to immune checkpoint inhibitor use.
Guha A; Al-Kindi S; Jain P; Tashtish N; ElAmm C; Oliveira GH
Int J Cancer; 2020 Sep; 147(6):1753-1754. PubMed ID: 32159861
[No Abstract] [Full Text] [Related]
23. Imaging Edema in Immune Checkpoint Inhibitor Myocarditis: A Moving Target.
Arcari L; Camastra G; Ciolina F; Danti M; Cacciotti L
J Am Coll Cardiol; 2021 Jul; 78(4):416-417. PubMed ID: 34294276
[No Abstract] [Full Text] [Related]
24. Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors.
Ji C; Roy MD; Golas J; Vitsky A; Ram S; Kumpf SW; Martin M; Barletta F; Meier WA; Hooper AT; Sapra P; Khan NK; Finkelstein M; Guffroy M; Buetow BS
Clin Cancer Res; 2019 Aug; 25(15):4735-4748. PubMed ID: 31085720
[TBL] [Abstract][Full Text] [Related]
25. Successful Treatment of Steroid-Refractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review.
Barry T; Gallen R; Freeman C; Agasthi P; Pedrotty D; Yang M; Jokerst CE; Mookadam F; Hardaway BW; LeMond L; Arsanjani R; Larsen C
Am J Med Sci; 2021 Oct; 362(4):424-432. PubMed ID: 33974854
[TBL] [Abstract][Full Text] [Related]
26. Monitoring of the Evolution of Immune Checkpoint Inhibitor Myocarditis With Cardiovascular Magnetic Resonance.
Sato T; Nakamori S; Watanabe S; Nishikawa K; Inoue T; Imanaka-Yoshida K; Ishida M; Sakuma H; Ito M; Dohi K
Circ Cardiovasc Imaging; 2020 Nov; 13(11):e010633. PubMed ID: 33153280
[No Abstract] [Full Text] [Related]
27. [Checkpoint inhibitor-induced myocarditis].
Gulati G; Tjessem KH; Horndalsveen H; Halvorsen S; Haakensen VD
Tidsskr Nor Laegeforen; 2022 Dec; 142(18):. PubMed ID: 36511752
[TBL] [Abstract][Full Text] [Related]
28. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Value of the International Society of Cardio-Oncology Definition for Suspected Immune Checkpoint Inhibitor-Associated Myocarditis.
Deharo F; Thuny F; Cadour F; Resseguier N; Meilhac A; Gaubert M; Dolladille C; Paganelli F; Alexandre J; Cautela J
J Am Heart Assoc; 2023 Apr; 12(8):e029211. PubMed ID: 37042287
[No Abstract] [Full Text] [Related]
30. Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy.
Sobol I; Chen CL; Mahmood SS; Borczuk AC
Arch Pathol Lab Med; 2020 Nov; 144(11):1392-1396. PubMed ID: 32150459
[TBL] [Abstract][Full Text] [Related]
31. Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients.
Ansari-Gilani K; Tirumani SH; Smith DA; Nelson A; Alahmadi A; Hoimes CJ; Ramaiya NH
Emerg Radiol; 2020 Aug; 27(4):455-460. PubMed ID: 32130542
[TBL] [Abstract][Full Text] [Related]
32. Use of abatacept in steroid refractory, immune checkpoint-induced myocarditis.
Kalapurackal Mathai V; Black A; Lovibond S; Binny S; Lipton J; Moldovan C
Intern Med J; 2021 Nov; 51(11):1971-1972. PubMed ID: 34796633
[No Abstract] [Full Text] [Related]
33. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.
Wang F; Sun X; Qin S; Hua H; Liu X; Yang L; Yang M
Chin Clin Oncol; 2020 Apr; 9(2):16. PubMed ID: 32279526
[TBL] [Abstract][Full Text] [Related]
34. Emerging causes and risk factors of heart failure: amyloidosis, myocarditis, immune checkpoint inhibitors, air pollution, and visceral adipose tissue.
Crea F
Eur Heart J; 2021 Apr; 42(16):1533-1537. PubMed ID: 33882575
[No Abstract] [Full Text] [Related]
35. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
36. Acute Myocarditis After Discontinuation of Immune Checkpoint Inhibitor Therapy.
Tamura Y; Tamura Y; Taniguchi H; Imanaka-Yoshida K
Circ J; 2023 Jan; 87(2):376. PubMed ID: 36310041
[No Abstract] [Full Text] [Related]
37. Subclinical Myocarditis After Combination Immune Checkpoint Inhibitor Therapy.
Giblin GT; Dennehy C; Featherstone H; Clarke R; Murphy L; Timlin D; O'Keane C; Mulligan N; Kelly CM; Joyce E
Circ Heart Fail; 2021 Feb; 14(2):e007524. PubMed ID: 33478241
[No Abstract] [Full Text] [Related]
38. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature.
Bi H; Ren D; Wang Q; Ding X; Wang H
Ann Palliat Med; 2021 Jan; 10(1):793-802. PubMed ID: 33545801
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Waliany S; Lee D; Witteles RM; Neal JW; Nguyen P; Davis MM; Salem JE; Wu SM; Moslehi JJ; Zhu H
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():113-134. PubMed ID: 32776859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
